27.07.2016: TRIANGLE Study was initiated in the first 2 German centers!

The TRIANGLE trial was successfully initiated at the first 2 centers in Germany.
In this study patients with initial diagnosis of Mantle Cell Lymphoma who are eligible for intensive treatment with high dose chemotherapy and autologous PBSCT will be included.
The study challenges the current standard of care and questions, whether the addition of ibrutinib to the standard results in a superior clinical outcome. In addition, we investigate whether ASCT which sometimes is hampered by short and long term toxicity is still superior to a (hopefully much better tolerated) conventional treatment without ASCT and with the addition of ibrutinib in induction and maintenance.